On 16 September 2026 the FDA's Drugs@FDA database recorded a supplement to abbreviated new drug application 202862, a generic olanzapine held by Macleods Pharmaceuticals.
A supplement to a generic application is usually a change to manufacturing, labelling alignment with the reference product, or packaging. The record does not state what changed, and nothing in it signals a new safety finding or a change in how olanzapine should be used.
The holder is an Indian manufacturer, so the product may share supply chains with olanzapine dispensed here, but the FDA action has no direct bearing on Indian prescribing.
- No change to olanzapine prescribing follows from this notice.
- Keep monitoring weight, glucose and lipids on olanzapine as usual.
- Generic olanzapine products are expected to be bioequivalent to the reference product.
Why it matters
Most regulatory traffic is housekeeping, and knowing that keeps attention for the notices that are not.
Don't overread it
A supplement to a generic application is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free